Monitor actual ATM sales volume and pace; the company has broad discretion over timing and amount. No immediate catalyst—watch for subsequent prospectus supplements or 10-Q disclosures revealing utilization. The ATM provides financial flexibility but will dilute existing holders over time.
Price Chart
Executive Summary
Twist Bioscience filed an automatic shelf registration (S-3ASR) including a base prospectus for various securities and a specific at-the-market (ATM) offering of up to $200M of common stock through TD Cowen. The ATM provides flexible capital-raising capacity for general corporate purposes, representing ~3.8% of the current $5.2B market cap. The filing is routine for a well-known seasoned issuer and does not indicate financial distress.
Key Facts
- S-3ASR filed June 18, 2026, as a well-known seasoned issuer
- Includes ATM sales agreement for up to $200M of common stock through TD Cowen
- TD Cowen commission capped at 3% of gross proceeds
- Net proceeds to be used for working capital and general corporate purposes
- As of March 31, 2026: 62,154,412 shares outstanding; net tangible book value $359.9M ($5.79/share)
- Pro forma dilution of $76.37/share at assumed $84.95 offering price
- Company has no current commitments for acquisitions or specific use of proceeds
Financial Impact
Up to $200M gross proceeds; ~3.8% dilution relative to $5.2B market cap; pro forma net tangible book value increases to ~$553.3M ($8.58/share)
Risk Factors
- Potential dilution from future ATM sales at uncertain prices
- Stock price pressure from continuous offering overhang
- Management discretion over proceeds may lead to value-destructive uses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3ASR Filing (Primary) | 0001104659-26-075726 |
| Document: tm2617605-1_s3asr.htm | 0001104659-26-075726 |
| Document: tm2617605d2_ex1-2.htm | 0001104659-26-075726 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | Insider Cluster | $127.22 $166.99 | ▲ +31.26% | ▲ +31.60% | $188.67 (+48.30%) |
Aug 27, 2026 5w ago | Insider Cluster | $153.10 $128.71 | ▼ −15.93% | ▼ −16.20% | $188.67 (+23.23%) |
Aug 25, 2026 5w ago | Insider Cluster | $151.42 $132.06 | ▼ −12.79% | ▼ −12.25% | $188.67 (+24.60%) |
Aug 21, 2026 6w ago | Insider Cluster | $145.59 $141.38 | ▼ −2.89% | ▼ −3.37% | $188.67 (+29.59%) |
Aug 20, 2026 6w ago | Insider Cluster | $136.23 $153.10 | ▲ +12.38% | ▲ +11.27% | $188.67 (+38.49%) |
Aug 14, 2026 7w ago | Insider Cluster | $124.41 $140.80 | ▲ +13.17% | ▲ +14.36% | $188.67 (+51.65%) |
Aug 14, 2026 7w ago | Insider Cluster | $124.41 $140.80 | ▼ −13.17% | ▼ −14.36% | $188.67 (−51.65%) |
Aug 12, 2026 7w ago | Insider Cluster | $125.29 $136.23 | ▲ +8.73% | ▲ +10.70% | $188.67 (+50.59%) |
Aug 12, 2026 7w ago | 144 | $125.29 $136.23 | ▲ +8.73% | ▲ +10.70% | $188.67 (+50.59%) |
Aug 11, 2026 7w ago | Insider Cluster | $123.12 $116.10 | ▼ −5.70% | ▼ −5.30% | $188.67 (+53.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access